Products

Description

Voglibose is an alpha-glucosidase inhibitor; it is an oral anti-diabetic drug used for Type 2 Diabetes mellitus. Alpha glucosidase inhibitors delay glucose absorption at the intestine level and thereby prevent sudden surge of glucose after a meal. Hence, alpha glucosidase inhibitors reduce the impact of complex carbohydrates on blood sugar and decreases the Post Prandial Hyperglycemia in diabetes and thereby reduces the risk of macrovascular complications.

Metformin is the oral anti hyperglycemic drug used in the management of Type 2 diabetes. It is the class of biguanides. Metformin improves glucose tolerance in patients with Type 2 diabetes; Metformin lowers both basal and postprandial blood glucose. Metformin decreases hepatic glucose production, decreases intestinal absorption of glucose and improves peripheral glucose uptake and utilization.

VOLIPHAGE-M0.2^® / VOLIPHAGE-M0.3^® TABLETS

(ORAL ANTI-HYPERGLYCEMIC AGENT)

Composition

VOLIPHAGE - M™ 0.2

Each uncoated bilayered tablet contains:
Voglibose ...................................................................... 0.2 mg.
Metformin Hydrochoride I.P............................................500 mg.
(In Sustained Release form)
Excipients …………………………………………………….q.s.
Colour: Lake of Sunset Yellow FCF (C.I. No. 15985)

VOLIPHAGE - M™ 0.3

Each uncoated bilayered tablet contains:
Voglibose . .................................................................... 0.3 mg.
Metformin Hydrochoride I.P............................................500 mg.
(In Sustained Release form)
Excipients ……………………………………………………q.s.
Colour: Lake of Quinoline Yellow (C.I. No. 47005)